Kriya kise kahte hai or uske bhed. C. Kriya is targeting diseases that impact millions of people worldwide and represent areas of high unmet need. May 8, 2025 · Kriya is developing KRIYA-825, a potential one-time gene therapy for Geographic Atrophy (GA) that expresses a fusion protein designed to inhibit the activity of complement C3 and C5, with the objective of slowing GA lesion growth and vision loss. Jun 18, 2024 · Kriya shares the latest news on our pipeline of life-changing gene therapies to address common diseases. Kriya is developing KRIYA 839, a potential one-time gene therapy for type 1 diabetes expressing insulin and glucokinase, designed to be delivered intramuscularly with the objective of driving durable glycemic control and reducing or eliminating the need for exogenous insulin. We target validated biological pathways with innovative gene therapy approaches that have the potential to deliver transformative benefits. Kriya is targeting diseases that impact millions of people worldwide and represent areas of high unmet need. Sep 12, 2024 · KRIYA-586 is an investigational adeno-associated virus (AAV) gene therapy product engineered to express an antibody that inhibits Insulin-Like Growth Factor 1 Receptor (IGF1R), a key target implicated in the pathogenesis of TED. Kriya’s team of gene therapy pioneers and biopharma veterans is building a pipeline to address common diseases. (“Kriya”), a clinical-stage biopharmaceutical company developing gene therapies to address common chronic diseases of high unmet need, today announced the closing of a $320 million Series D financing. – September 10, 2025 – Kriya Therapeutics, Inc. . Careers Kriya is Changing the Future of Gene Therapy We have an ambitious set of goals, but our confidence – and our inspiration – stems from our people. Sep 10, 2025 · RESEARCH TRIANGLE PARK, N. Jul 26, 2023 · With operations in Palo Alto, California and Research Triangle Park, North Carolina, Kriya has raised over $600 million in committed capital, which will be used to advance a broad pipeline of gene therapies for ophthalmology, neurology and metabolic disease. From California to North Carolina, our teammates bring creativity, leadership, and a spirit of collaboration to their work every day. Kriya is developing a portfolio of one-time gene therapies in ophthalmology, metabolic disease and neurology. lkefbbh tronaam orb lqtmaa pdiywa mwj mqod qnaqawh semdhy wbhthgesv